Guardant Health, Inc. is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes. Guardant360 CDx has received regulatory approval as a companion diagnostic for targeted therapies, while Guardant Reveal offers a blood-based solution for minimal residual disease (MRD) monitoring in early-stage colorectal cancer. Guardant Health is also developing its LUNAR platform for multi-cancer early detection through screening applications.
Guardant Health operates CLIA-certified, CAP-accredited laboratories in the United States and has expanded service offerings across Europe and Asia through partnerships and regional laboratory certifications. The company collaborates with pharmaceutical and biotechnology firms on clinical trials to accelerate drug development and optimize patient selection for targeted therapies. Its commercial and research testing services support oncology practices, academic institutions and life science organizations globally.
The company was co-founded by Helmy Eltoukhy, who serves as Chief Executive Officer, and AmirAli Talasaz, President and Co-founder. Under their leadership, Guardant Health has grown its product pipeline, secured regulatory clearances and forged strategic alliances to advance the use of liquid biopsy in precision oncology.
AI Generated. May Contain Errors.
